Clinical Trial Update: A Master Protocol for Semaglutide Effects on Cardiovascular and Obesity-related Outcomes in People With Overweight or Obesity in the Real World

View source ↗

Summary

A completed master protocol study evaluating the effects of semaglutide on cardiovascular and obesity-related outcomes in real-world adults who are overweight o…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atherosclerotic Cardiovascular Disease
• Heart Failure
• Obesity
• Overweight

Drugs mentioned

• semaglutide (semaglutide)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Overweight, Obesity | Status: COMPLETED